Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 7/20 | 0.72 |
| ▸ | MEP1A | Q16819 | 2/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417375 | 0.92 | MEP1B (0.76) | MEP1BMEP1AHDAC1HDAC3HDAC2 | |
| SCHEMBL19478234 | 0.92 | MEP1B (0.76) | MEP1BMEP1AHDAC1HDAC3HDAC2 | |
| SCHEMBL19478281 | 0.84 | HDAC1 (0.61) | MEP1BMEP1AHDAC1HDAC3HDAC2 | |
| SCHEMBL19510175 | 0.84 | MEP1B (1.00) | MEP1BMEP1ALMNA | |
| SCHEMBL20952239 | 0.79 | HDAC1 (0.91) | MEP1BHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL6510744 | 0.76 | MEP1B (0.56) | MEP1BMEP1ALMNA | |
| SCHEMBL19474704 | 0.75 | MEP1B (0.55) | MEP1BMEP1AHDAC1HDAC3HDAC2 | |
| SCHEMBL28733027 | 0.75 | MEP1B (0.64) | MEP1BMEP1ALMNAMAOAMAOB | |
| SCHEMBL13783921 | 0.74 | HDAC1 (0.83) | MEP1BHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL28764949 | 0.74 | MEP1A (0.56) | MEP1BMEP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| EP-3967679-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Vivoryon Therapeutics AG (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| WO-2017182433-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC1 1506/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC1 1606/4885 |
| US-10975019-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.